exp3174 and losartan
exp3174 has been researched along with losartan in 226 studies
Compound Research Comparison
| Studies (exp3174) | Trials (exp3174) | Recent Studies (post-2010) (exp3174) | Studies (losartan) | Trials (losartan) | Recent Studies (post-2010) (losartan) |
|---|---|---|---|---|---|
| 236 | 29 | 43 | 7,231 | 1,245 | 2,118 |
Protein Interaction Comparison
| Protein | Taxonomy | exp3174 (IC50) | losartan (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 9.01 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.882 | |
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.019 | |
| Atrial natriuretic peptide receptor 3 | Homo sapiens (human) | 0.0018 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.019 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0247 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0234 | |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | 0.0032 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.047 | |
| Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | 0.025 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0118 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.019 | |
| Platelet glycoprotein VI | Homo sapiens (human) | 4 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.1481 | |
| Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.2884 |
Research
Studies (226)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 116 (51.33) | 18.2507 |
| 2000's | 62 (27.43) | 29.6817 |
| 2010's | 40 (17.70) | 24.3611 |
| 2020's | 8 (3.54) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Boyd, DB; Lin, HS; Rampersaud, AA; Steinberg, MI; Zimmerman, K | 1 |
| Belvisi, L; Caliari, S; Canevotti, R; Cirillo, R; Fici, F; Paleari, F; Poma, D; Renzetti, AR; Salimbeni, A; Subissi, A | 1 |
| Chakravarty, PK; Chang, RS; Chen, A; Chen, TB; Faust, KA; Gable, RA; Kivlighn, SD; Lotti, VJ; Naylor, EM; Zingaro, GJ | 1 |
| Ashton, WT; Chakravarty, PK; Chang, LL; Chen, TB; Faust, KA; Flanagan, KL; Greenlee, WJ; Hutchins, SM; Naylor, EM; Patchett, AA | 1 |
| Ashton, WT; Chang, RS; Chen, TB; Doss, GA; Faust, KA; Greenlee, WJ; Hutchins, SM; Kivlighn, SD; Lotti, VJ; Zingaro, GJ | 1 |
| Ashton, WT; Chang, LL; Chang, RS; Chen, TB; Faust, KA; Flanagan, KL; Greenlee, WJ; Lotti, VJ; MacCoss, M; Strelitz, RA | 1 |
| Bunker, AM; Connolly, C; Edmunds, JJ; Hamby, JM; Hodges, JC; Kesten, SJ; Kostlan, CR; Quin, J; Sircar, I; Winters, RT | 1 |
| Benfield, P; Carini, DJ; Chiu, AT; Herblin, WF; Lee, RJ; Saye, JA; Smith, RD; Timmermans, PB; Wexler, RR; Wong, PC | 1 |
| Altenbach, RJ; Basha, FZ; Boyd, SA; Brune, ME; Buckner, SA; Crowell, D; De, B; Drizin, I; Winn, M; Zydowsky, TM | 1 |
| Ashton, WT; Cantone, CL; Chang, LL; Chang, RS; Chen, TB; Faust, KA; Hutchins, SM; Lotti, VJ; MacCoss, M; Strelitz, RA | 1 |
| Amemiya, Y; Fujimoto, K; Furukawa, Y; Ikeda, M; Kanazaki, T; Kitahara, Y; Koike, H; Miyamoto, S; Mizuno, M; Sada, T; Shimoji, Y; Yanagisawa, H | 1 |
| Goldberg, MR; Greenlee, WJ; Irvin, JD; Prendergast, K; Smith, RD; Timmermans, PB; Wexler, RR | 1 |
| Almansa, C; Cavalcanti, FL; de Arriba, AF; Forn, J; García-Rafanell, J; Gómez, LA | 1 |
| Krovat, EM; Langer, T | 1 |
| Berellini, G; Cruciani, G; Mannhold, R | 1 |
| Balsamo, A; Breschi, MC; Calderone, V; Digiacomo, M; Macchia, M; Martelli, A; Martinotti, E; Minutolo, F; Rapposelli, S; Rossello, A; Testai, L | 1 |
| Giridhar, R; Murumkar, P; Naik, P; Yadav, MR | 1 |
| Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T | 1 |
| Alajarín, R; Alvarez-Builla, J; Díez-Marqués, ML; García, G; Griera, M; Rodríguez-Puyol, D; Rodríguez-Puyol, M; Sánchez-Alonso, P; Serrano, I; Vaquero, JJ | 1 |
| Abad-Santos, F; Cabaleiro, T; López-Rodríguez, R; Novalbos, J; Ochoa, D; Prieto-Pérez, R; Román, M; Talegón, M; Wojnicz, A | 1 |
| Benachour, N; Vanderheyden, PML | 1 |
| Cramer, J; Ernst, B; Sager, CP | 1 |
| Brunner, HR; Christen, Y; Lee, RJ; Munafo, A; Nussberger, J; Waeber, B | 1 |
| Brooks, DP; DePalma, PD; Ruffolo, RR | 1 |
| Chen, SJ; Jin, H; Oparil, S; Wyss, JM; Yang, RH | 1 |
| Bennett, T; Gardiner, SM; Kemp, PA; Widdop, RE | 4 |
| Hood, JS; Kadowitz, PJ; Kaye, AD; McMahon, TJ; Minkes, RK; Nossaman, BD | 1 |
| Clozel, JP; Fischli, W; Hess, P; Véniant, M | 1 |
| Biollaz, J; Borland, RM; Brunner, HR; Christen, Y; Lee, RJ; Munafo, A; Nussberger, J; Shum, LY; Waeber, B | 1 |
| Furtek, CI; Lo, MW | 1 |
| Entzeroth, M; Mauz, AB; Van Meel, JC; Wienen, W | 1 |
| Chakravarty, PK; Chang, RS; Clineschmidt, BV; Greenlee, WJ; Lotti, VJ; Mantlo, NB; Patchett, AA; Siegl, PK | 1 |
| Chakravarty, PK; Chang, RS; Greenlee, WJ; Lotti, VJ; Mantlo, NB; Ondeyka, DL; Patchett, AA; Siegl, PK; Sweet, CS | 1 |
| Brooks, DP; Edwards, RM; Fredrickson, TA; Gellai, M; Ruffolo, RR; Weinstock, J | 1 |
| Duncia, JV; Hart, SD; Timmermans, PB; Wong, PC | 1 |
| Carini, DJ; Chiu, AT; Duncia, JV; Johnson, AL; Price, WA; Timmermans, PB; Wells, GJ; Wexler, RR; Wong, PC | 1 |
| Hart, SD; Timmermans, PB; Wong, PC | 1 |
| Carini, DJ; Chiu, AT; Duncia, JV; Johnson, AL; Price, WA; Timmermans, PB; Wexler, RR; Wong, PC | 1 |
| Baker, KM; Conrad, KM; Dostal, DE; Schorb, W; Singer, HA | 1 |
| Ciccocioppo, R; Cirillo, R; Massi, M; Polidori, C; Pompei, P | 2 |
| Baker, KM; Bhat, GJ; Conrad, KM; Thekkumkara, TJ; Thomas, WG | 1 |
| Kunihara, M; Kushida, H; Morita, O | 1 |
| Bartholomeusz, B; Widdop, RE | 1 |
| Baker, KM; Dostal, DE; Du, J; Motel, TJ; Thekkumkara, TJ; Thomas, WG | 1 |
| Christ, DD | 1 |
| Berdeaux, A; Giudicelli, JF; Richard, V | 1 |
| Berman, RS; Bradstreet, DC; Jallard, N; Saenz, A; Sweet, CS; Weidler, DJ | 1 |
| Chakravarty, PK; Chen, R; Chiu, SH; Stearns, RA | 1 |
| Guengerich, FP; Jeong, HG; Lee, H; Lee, HS; Rho, JK; Yun, CH | 1 |
| Fink, GD; Gorbea-Oppliger, VJ | 1 |
| Fujishima, K; Hachisu, M; Hui, C; Katano, K; Kawano, K; Konno, F; Nagura, J; Ogino, H; Yamamoto, M; Yasuda, S | 1 |
| Bauer, JH; Reams, GP | 1 |
| Cohen, RB; Delaney, CL; Dickinson, KE; Gu, Z; Moreland, S; Poss, MA; Powell, JR; Ryono, DE; Serafino, RP; Skwish, S | 1 |
| Basso, N; Cannata, MA; Kurnjek, ML; Ruiz, P | 1 |
| Hodgson, WC; Hopkins, BJ; Sutherland, SK | 1 |
| Bennett, T; Gardiner, SM; Widdop, RE | 1 |
| Chiu, AT; Keiser, J; Madison, AB; Nishimura, H; Patton, CM; Walker, OE | 1 |
| Ishizaki, H; Ohtawa, M | 1 |
| Ardaillou, R; Bizet, T; Chansel, D; Levy, B; Pham, P; Vandermeersch, S | 1 |
| Bensoussan, M; Mitchell, T; Reilly, T; Ronco, PM; Timmermans, PB; Verroust, PJ | 1 |
| Berdeaux, A; Ghaleh, B; Giudicelli, JF; Richard, V | 1 |
| Aki, Y; Fukui, T; He, H; Iwao, H; Kimura, S; Miyatake, A; Nishiyama, A; Tamaki, T; Yamamoto, A; Yoshida, H | 1 |
| Inada, Y; Kohara, Y; Kubo, K; Naka, T; Nishikawa, K; Noda, M; Ojima, M; Sanada, T; Shibouta, Y; Wada, T | 1 |
| Christian, R; Düsing, R; Ko, Y; Meyer zu Brickwedde, MK; Sachinidis, A; Vetter, H; Weisser, P; Wieczorek, AJ | 1 |
| Bellan, JA; Kadowitz, PJ; Minkes, RK; Osei, SY | 1 |
| Nakashima, M; Ohtawa, M; Saitoh, K; Takayama, F; Yoshinaga, T | 1 |
| Ardaillou, R; Badre, L; Cambar, J; Chansel, D; Czekalski, S; Vandermeersch, S | 1 |
| Bjornsson, TD; Furtek, CI; Goldberg, MR; Lo, MW; Lu, H; McCrea, JB | 1 |
| Edwards, RM; Stack, EJ; Trizna, W; Weinstock, J | 1 |
| Deutsch, PJ; Goldberg, MR; Lo, MW; McCrea, JB; McWilliams, EJ; Wilson, SE | 1 |
| Bradstreet, TE; Goldberg, MR; Höglund, P; Lo, MW; Ritter, MA | 1 |
| Li, XC; Widdop, RE | 1 |
| Dunham, EW; Zhang, X; Zimmerman, BG | 1 |
| Bosch, SM; Diz, DI; Li, Z; Smith, TL | 1 |
| Baan, J; Chang, PC; Pfaffendorf, M; van Zwieten, PA; Vermeij, P | 1 |
| Christ, DD; Lam, GN; Wong, PC; Wong, YN | 1 |
| Feng, YH; Husain, A; Karnik, SS; Liu, XP; Noda, K; Saad, Y | 1 |
| Dunn, FW; Farhadian, F; Hamon, G; Ossart, C; Rappaport, L; Roux, MH; Sabri, K; Samuel, JL | 1 |
| Caussade, F; Cazes, M; Cloarec, A; Desangle, V; Provost, D; Virone-Oddos, A | 1 |
| Harada, Y; Hashimoto, Y; Murata, S; Naito, K; Narita, H | 1 |
| Arendshorst, WJ; Chatziantoniou, C; Kurtz, A; Ruan, X; Wagner, C | 1 |
| Armentano, RL; Barra, JG; Cabrera Fischer, EI; Levenson, J; Pichel, RH; Simon, A | 1 |
| Goldsmith, DJ | 1 |
| Furtek, CI; Lo, MW; Ritter, MA | 1 |
| Baker, KM; Conrad, KM; Dostal, DE; Hunt, RA; McWhinney, CD | 1 |
| Blum, RA; Boike, SC; Etheredge, R; Ilson, B; Jorkasky, DK; Kazierad, DJ; Martin, DE; Tenero, DM | 1 |
| Fujimori, A; Inagaki, O; Kusayama, T; Okazaki, T; Satoh, Y; Shibasaki, M; Takanashi, M; Tokioka, T; Uchida, W; Yanagisawa, I | 1 |
| Bai, SA; Christ, DD; Hellyer, P; Lankford, SM; Plummer, D | 1 |
| Heller, J; Horácek, V | 1 |
| Heller, J; Horácek, V; Kramer, HJ | 1 |
| Fleischhauer, J; Hanrath, P; Klues, HG; Montino, H; Schwarz, ER; vom Dahl, J | 1 |
| Fakhry, I; Farthing, D; Gehr, TW; Pedro, A; Sica, D | 1 |
| Hong, KW; Kim, CD; Lee, SH; Yoo, SE | 1 |
| Mangiapane, ML; Peters, BR | 1 |
| Mutschler, E; Soldner, A; Spahn-Langguth, H | 1 |
| Adams, KF; McQueen, RH; Patterson, JH; Pieper, JA; Williamson, KM | 1 |
| Kaukonen, KM; Neuvonen, PJ; Olkkola, KT | 1 |
| Mutschler, E; Palm, D; Soldner, A; Spahn-Langguth, H | 1 |
| Kimura, R; Miyake, H; Nozawa, Y; Yamada, S | 1 |
| Fujimori, A; Inagaki, O; Kikuchi, K; Okazaki, T; Shibasaki, M; Suga, A; Watanabe, T; Yanagisawa, I | 1 |
| Busse, R; Fisslthaler, B; Fleming, I; Schini-Kerth, VB | 1 |
| Brosnihan, KB; Ferrario, CM; Li, P | 1 |
| Freel, RW; Hatch, M; Vaziri, ND | 1 |
| Carini, DJ; Christ, DD; Duncia, JV; Pierce, ME | 1 |
| Baik, EJ; Jung, YS; Lee, HJ; Lee, SH; Moon, CH | 1 |
| Iouzalen, L; Marche, P; Stepien, O | 1 |
| Bjornsson, T; Cribb, A; Gillen, L; Goldberg, MR; Lo, MW; McCrea, JB; Osborne, B; Rushmore, T; Spielberg, S; Waldman, S | 1 |
| Harris, PJ; Hiranyachattada, S; Smart, ML | 1 |
| Barbe, F; Crozatier, B; Guyene, TT; Hittinger, L; Houël, R; Su, J | 1 |
| Abrahamsson, T; Adler, G; Brandt-Eliasson, U; Karp, L; Morsing, P; Ohlson, K; Renberg, L; Sjöquist, PO | 1 |
| De Backer, JP; Fierens, FL; Vanderheyden, PM; Vauquelin, G | 1 |
| Oberhauser, V; Rump, LC; Schwertfeger, E | 1 |
| Garcha, RS; Hughes, AD; Sever, PS | 1 |
| Gould, RJ; Grossman, W; Kusma, SE; Lynch, JJ; Painter, CA; Stump, GL; Thomas, JM; Wallace, AA | 1 |
| Hashimoto, Y; Narita, H; Yabana, H | 1 |
| Cheung, PK; Saward, L; Wilson, DP; Zahradka, P | 1 |
| Hashimoto, Y; Minami, K; Narita, H; Ohashi, R | 1 |
| Hara, K; Iwasa, T; Kamei, T; Takano, T | 1 |
| Ardaillou, R; Chansel, D; Llorens-Cortes, C; Vandermeersch, S | 1 |
| Coca, A; Giner, V | 1 |
| Kato, H; Tajima, S; Takata, Y | 1 |
| Caballero, R; Delpón, E; Longobardo, M; Tamargo, J; Valenzuela, C | 1 |
| Benet, LZ; Christians, U; Mutschler, E; Soldner, A | 1 |
| Casado, S; Castilla, C; Farré, J; Gómez, J; Guerra, JI; Jiménez, AM; López-Farré, A; Marcos, P; Montón, M; Núñez, A; Rico, L; Rodríguez-Feo, JA; Sánchez De Miguel, L | 1 |
| Brophy, DF; Gehr, TW; Pedro, AA; Sica, DA | 1 |
| Cervenka, L; Heller, J; Horácek, V; Kramer, HJ; Malý, J | 1 |
| deBlois, D; Hou, Y; Lemay, J | 1 |
| Casado, S; Farré, J; Gómez, J; Jiménez, A; López-Blaya, A; López-Farré, A; Montón, M; Núñez, A; Sánchez de Miguel, L; Zalba, LR | 1 |
| Hatta, E; Levi, R; Maruyama, R; Smith, NC; Yasuda, K | 1 |
| Casley, DJ; Dinh, DT; Fabiani, ME; Johnston, CI; Nassis, L | 1 |
| Fice, D; Jamieson, A; Pollak, PT; Smith, GJ; Yeung, PK | 1 |
| Alova, L; Georgiev, V; Stancheva, S | 1 |
| Buczko, W; Chabielska, E; Chłopicki, S; Gryglewski, RJ; Koda, M | 1 |
| Hanada, K; Ikeda, T; Ikemoto, F; Kawai, N; Nakao, M; Nishikibe, M; Ohta, H; Suzuki, J | 1 |
| Jankowski, J; Schlüter, H; Schmid, A; Tepel, M; van der Giet, M; Zidek, W | 1 |
| Avni, B; Dishi, V; Gips, M; Golik, A; Scapa, E; Soback, S; Weissgarten, Y; Zaidenstein, R | 1 |
| Bassenge, E; Schwemmer, M; Sommer, O | 1 |
| Dahl, ML; Dorado, P; Eliasson, E; Forslund-Bergengren, C; Llerena, A; Sjöqvist, F; Tybring, G; Yasar, U | 1 |
| Böger, RH; Drexler, H; Forssmann, WG; Krämer, C; Luchtefeld, M; Schieffer, B; Schmidt, B; Sunkomat, J; Tsikas, D; Walden, M; Witte, J | 1 |
| Rane, A; Sandberg, M; Xie, HJ; Yasar, U | 1 |
| Koyama, M; Levi, R; Mackins, CJ; Seyedi, N | 1 |
| Buczko, W; Chabielska, E; Kalinowski, L; Malinski, T; Matys, T | 1 |
| Buczko, W; Kucharewicz, I; Matys, T; Pawlak, D; Pawlak, R | 1 |
| Edvinsson, L; Malmsjö, M; Pantev, E; Stenman, E; Wackenfors, A | 1 |
| Dobrucki, LW; Heitsch, H; Louka, FR; Malinski, T; Wiemer, G | 1 |
| Chiba, S; Inada, Y; Nakane, T | 1 |
| Boonstra, PW; Buikema, H; Lübeck, RH; van Buiten, A; van Gilst, WH; van Veldhuisen, DJ; Voors, AA; Wagenaar, LJ | 1 |
| Hunyady, L; Kersemans, V; Le, MT; Szaszák, M; Vanderheyden, PM; Vauquelin, G | 1 |
| De Backer, JP; Vanderheyden, P; Vauquelin, G; Verheijen, I | 1 |
| Blaisdell, JA; Goldstein, JA; Hinderliter, AL; Lee, CR; Pieper, JA | 1 |
| Bessard, G; Caron, F; Cracowski, JL; Hakim, A; Hoffmann, P; Sessa, C; Stanke-Labesque, F | 1 |
| Lo, MW; Polinko, M; Riffel, K; Song, H | 1 |
| Horiuchi, R; Iga, T; Kimura, K; Kubota, T; Okada, Y; Sekino, K; Yamada, Y; Yamamoto, K | 1 |
| Alova, L; Georgiev, V; Stancheva, S; Velkova, M | 1 |
| Bäcker, A; Heller, J; Horacek, V; Kramer, HJ; Vaneckova, I | 1 |
| Dominiak, P; Häuser, W | 1 |
| Buczko, W; Chabielska, E; Domaniewski, T; Kucharewicz, I; Matys, T; Pawlak, R | 1 |
| Gogonea, C; Karnik, SS; Noda, K; Saad, Y; Takezako, T | 1 |
| Daliani, I; Dimitriou, D; Kamoutsis, C; Kyrikou, I; Laggner, P; Mavromoustakos, T; Pitsas, A; Siapi, E; Zervou, M; Zoga, A; Zoumpoulakis, P | 1 |
| Avery, MA; Benson, SC; Chittiboyina, A; Desai, P; Ho, CI; Kurtz, TW; Pershadsingh, HA; Pravenec, M; Qi, N; Wang, J | 1 |
| Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM | 1 |
| Arguin, G; Auger-Messier, M; Chaloux, B; Escher, E; Guillemette, G; Leduc, R | 1 |
| Oberhauser, V; Rump, LC; Sellin, L; Stegbauer, J; Vonend, O | 1 |
| de Leeuw, PW; Fuss-Lejeune, MJ; Kroon, AA; Spiering, W | 1 |
| Auger-Messier, M; Escher, E; Guillemette, G; Leduc, R; Turgeon, ES | 1 |
| de Leeuw, PW; Kroon, AA; Spiering, W | 1 |
| Frost, N; Kintscher, U; Lee, LD; Schmidt, B; Schupp, M; Umbreen, S; Unger, T | 1 |
| Babaoglu, MO; Boruban, C; Bozkurt, A; Coskun, U; Gunel, N; Gunes, A; Hassan, M; Rane, A; Sencan, O; Yasar, U; Zengil, H | 1 |
| Guilbaud, R; Kambhampati, SR; Lee, J; Marier, JF; Mathew, P; Moberly, J; Salazar, DE | 1 |
| Calderone, V; Martinelli, A; Rapposelli, S; Tuccinardi, T | 1 |
| Apostolou, C; Dotsikas, Y; Kolocouri, F; Kousoulos, C; Loukas, YL | 1 |
| Koyabu, N; Kuwano, M; Murakami, H; Nakamura, T; Ohtani, H; Satoh, H; Sawada, Y; Tsujimoto, M; Uchiumi, T; Ushigome, F; Yamashita, F | 1 |
| Danielyan, L; Gleiter, CH; Kabisch, D; Lourhmati, A; Proksch, B; Schmidt, B; Thiess, U; Umbreen, S; Verleysdonk, S | 1 |
| Babaoglu, MO; Bilir, E; Bozkurt, A; Gunes, A; Yasar, U; Zengil, H | 1 |
| Furtek, CI; Gehr, TW; Halstenson, CE; Keane, WF; Lipschutz, K; Lo, MW; Ritter, MA; Shahinfar, S; Shaw, WC; Sica, DA | 1 |
| Chen, Y; Fan, L; Guo, D; Hu, DL; Li, Z; Peng, XJ; Qian, RH; Wang, G; Xiao, CQ; Zhou, HH | 1 |
| Chen, BL; Fan, L; Hu, DL; Li, Q; Li, Z; Liu, J; Liu, ZQ; Tan, ZR; Tu, JH; Wang, G; Wang, LS; Zhang, W; Zhou, HH | 1 |
| Bähr, IN; Fleck, E; Fritzsche, J; Goebel, M; Gust, R; Hässle, PL; Kappert, K; Kaufmann, J; Kintscher, U; Ott, I; Stawowy, P; Tsuprykov, O; Unger, T | 1 |
| Beloqui, O; Bidegain, J; Díez, J; Fortuño, A; Hermida, J; López-Sagaseta, J; Robador, PA; Zalba, G | 1 |
| Kundlik, ML; Patel, CN; Patel, DM; Patel, NK; Shah, HJ; Subbaiah, G; Suhagia, BN | 1 |
| Iliodromitis, EK; Kokotos, G; Kremastinos, DT; Mavromoustakos, TM; Moutevelis-Minakakis, P; Politi, AP; Triantafyllidi, H; Zervou, MV; Zoga, AA; Zoumpoulakis, PG | 1 |
| Arsenault, J; Cabana, J; Escher, E; Guillemette, G; Lanthier, L; Lavigne, P; Leduc, R; Lehoux, J | 1 |
| Choi, DH; Choi, JS; Li, C | 1 |
| Furukubo, T; Higuchi, K; Hirata, S; Izumi, S; Nishiguchi, K; Otagiri, M; Shima, D; Takara, K; Tsujimoto, M; Yamakawa, T; Yokota, H | 1 |
| Choi, HG; Kim, HK; Lee, GS; Lee, WS; Seo, KH; Woo, JS; Yan, YD; Yong, CS | 1 |
| Cho, YA; Choi, JS; Yang, SH | 1 |
| Choi, DH; Choi, JS; Yang, SH | 1 |
| Guo, T; Xia, DY; Yang, L; Zhao, LS | 1 |
| Bae, JW; Bang, HK; Choi, CI; Chung, MW; Ha, JH; Jang, CG; Kang, BS; Keum, SK; Kim, BH; Kim, HD; Kim, MJ; Kim, YH; Lee, SY; Na, HS; Oh, DH; Oh, SG; Park, HJ; Park, JI; Shin, HJ | 1 |
| Du, FY; Liu, AC; Liu, T; Lou, HX; Xing, J; Zhao, LX | 1 |
| Kim, DH; Oh, KS; Park, SJ; Shin, JG; Shinde, DD | 1 |
| Bae, JW; Choi, CI; Jang, CG; Lee, HI; Lee, SY; Lee, YJ | 1 |
| de Andrés, F; Dorado, P; Llerena, A; Machín, E; Naranjo, ME; Peñas-Lledó, EM | 1 |
| Batzias, G; Niopas, I; Spanakis, M; Vizirianakis, IS | 1 |
| Chai, Y; Ma, W; Sun, S; Wang, B; Yuan, Y; Zhang, G; Zhang, H; Zhao, L | 1 |
| Akamatsu, T; Chida, K; Inui, N; Karayama, M; Namiki, N; Tanaka, S; Uchida, S; Watanabe, H | 1 |
| Guo, R; Li, R; Lv, C; Wang, B; Wang, X; Wei, C; Yao, H | 1 |
| Choi, DH; Choi, JS | 1 |
| Arslanbekova, SM; Golukhova, EZ; Kazakov, RE; Kuznetsova, EV; Smirnov, VV; Sychev, DA | 1 |
| Breunig, M; Goepferich, A; Hennig, R; Pollinger, K; Veser, A | 1 |
| Akdogan, A; Babaoglu, MO; Bertilsson, L; Bozkurt, A; Goktaş, MT; Hatta, F; Helldén, A; Kalkisim, S; Karaca, O; Kilic, L; Yasar, U | 1 |
| Goepferich, A; Hennig, R; Kirchhof, S; Veser, A | 1 |
| Antoun, R; Beanlands, RS; DaSilva, JN; deKemp, RA; Hadizad, T; Ismail, B; Lortie, M | 1 |
| Srinivas, NR | 1 |
| Breunig, M; Goepferich, A; Haunberger, A; Hennig, R; Ohlmann, A; Pollinger, K; Schweda, F; Staffel, J; Tamm, ER | 1 |
| Jang, HJ; Kim, KB; Kim, YS; Ryu, SH | 1 |
| Eliasson, E; Inotsume, N; Mukai, Y; Rane, A; Senda, A; Toda, T | 1 |
| Wang, R; Wang, Y; Yu, X; Yuan, Y; Zhang, H | 1 |
| Gribakina, OG; Kolyvanov, GB; Litvin, AA; Shevchenko, RV; Smirnov, VV; Zherdev, VP | 1 |
| Clifford, PS; Davis, MJ; Hill, MA; Hong, K; Hong, Z; Meininger, GA; Sun, Z; Yang, Y; Zhao, G | 1 |
| Beaumont, J; Díez, J; Fortuño, A; González, A; López, B; Miguel-Carrasco, JL; Moreno, MU; Ravassa, S; San José, G; Zalba, G | 1 |
| Hu, Y; Shi, H; Shi, W; Ye, S; Zhang, H; Zhou, X | 1 |
| Prusty, S; Sahu, PK; Singh, VK; Subudhi, BB | 1 |
| Karalis, V; Karatza, E | 1 |
| Chabielska, E; Gromotowicz-Poplawska, A; Nazarko-Sadowska, J | 1 |
| Abadir, PM; Anders, NM; Bichara, MD; Buta, B; Carey, RM; de Cabo, R; Ferrucci, L; Gabrawy, MM; Khadeer, M; Kwak, MJ; Le, A; Lee, JL; Ma, L; Marx, R; Moaddel, R; Nidadavolu, L; Rudek, MA; Siragy, HM; Tian, J; Walston, JD; Westbrook, R; Wu, Y; Xue, QL; Yang, H; Yenokyan, G; Zhang, C | 1 |
| Atmuri, NDP; Bernatchez, P; Cait, J; Ciufolini, MA; Donen, G; Dong, Y; Hughes, M; McNagny, KM; Pechkovsky, D; Sauge, E; Sin, DD; Tam, A; Tehrani, AY; Walker, MJA; White, Z; Yuen, C | 1 |
| Bester, K; Kisielius, V; Li, R; Liang, C; Svendsen, SB | 1 |
| Akmalova, KA; Asoskova, AV; Boyarko, AV; Fisenko, VP; Grishina, EA; Mirzaev, KB; Sinitsina, II; Sozaeva, ZA; Sychev, DA; Temirbulatov, II | 1 |
| Alfarraj, S; Alharbi, SA; Almoallim, HS; Ansari, MJ; Dar, AA; Dar, SA; Hassan, GI; Jan, I; Khan, NA; Mir, KB; Raina, A; Sofi, JA; Tarique, M; Wani, TA; Wani, TU | 1 |
| da Silva Sólon, LG; Martin-Pastor, M; Queiroz, KA; Santos, ISR; Sousa, FFO; Tavares Júnior, AG | 1 |
| Bai, J; Cai, L; Miao, Z; Si, Y; Sun, J; Wei, Y; Xiao, Y; Xing, W; Ye, H | 1 |
Reviews
11 review(s) available for exp3174 and losartan
| Article | Year |
|---|---|
Angiotensin II receptors and angiotensin II receptor antagonists.
Topics: Amino Acid Sequence; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cloning, Molecular; Hemodynamics; Humans; Hypertension; Imidazoles; Kidney; Losartan; Molecular Sequence Data; Pyridines; Receptors, Angiotensin; Tetrazoles | 1993 |
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Humans; Receptors, Angiotensin; Structure-Activity Relationship | 1996 |
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Losartan | 2010 |
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
Topics: Angiotensin II Type 1 Receptor Blockers; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Kinetics; Ligands; Protein Binding; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Signal Transduction | 2017 |
Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group.
Topics: Biological Products; Hydrogen Bonding; Hydroxyl Radical; Ligands; Thermodynamics | 2019 |
Angiotensin II receptor antagonists. From discovery to antihypertensive drugs.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Humans; Imidazoles; Losartan; Receptors, Angiotensin; Tetrazoles | 1991 |
The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs.
Topics: Acrylates; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Losartan; Pyridines; Quinolines; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 1995 |
The discovery and development of angiotensin II antagonists.
Topics: Angiotensin II; Animals; Humans; Imidazoles; Losartan; Structure-Activity Relationship; Tetrazoles | 1998 |
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Heart Diseases; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 1999 |
Efforts to understand the molecular basis of hypertension through drug:membrane interactions.
Topics: Amino Acids; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Binding Sites; Biphenyl Compounds; Calorimetry, Differential Scanning; Cell Membrane; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Magnetic Resonance Spectroscopy; Models, Molecular; Receptor, Angiotensin, Type 1; Tetrazoles; X-Ray Diffraction | 2004 |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Nephropathies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2004 |
Trials
29 trial(s) available for exp3174 and losartan
| Article | Year |
|---|---|
Clinical experience with angiotensin II receptor antagonists.
Topics: Administration, Oral; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Humans; Hypertension; Imidazoles; Injections, Intravenous; Losartan; Renin-Angiotensin System; Tetrazoles; Time Factors | 1992 |
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist.
Topics: Administration, Oral; Adult; Aldosterone; Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biotransformation; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Humans; Imidazoles; Losartan; Male; Reference Values; Renin; Tetrazoles | 1992 |
Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin II; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Imidazoles; Injections, Intravenous; Kidney Function Tests; Losartan; Male; Middle Aged; Renin; Tetrazoles; Uric Acid | 1994 |
Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans.
Topics: Administration, Oral; Adult; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Heart Rate; Humans; Imidazoles; Losartan; Male; Middle Aged; Renin; Tetrazoles | 1993 |
Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans.
Topics: Administration, Oral; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cross-Over Studies; Humans; Imidazoles; Infusions, Intravenous; Losartan; Male; Tetrazoles | 1995 |
Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174.
Topics: Adult; Anticonvulsants; Antihypertensive Agents; Biphenyl Compounds; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Humans; Hydrocortisone; Hypnotics and Sedatives; Imidazoles; Losartan; Male; Mixed Function Oxygenases; Phenobarbital; Reference Values; Single-Blind Method; Tetrazoles | 1996 |
Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cimetidine; Cross-Over Studies; Histamine H2 Antagonists; Humans; Hypertension; Imidazoles; Losartan; Male; Tetrazoles | 1995 |
Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed of healthy volunteers.
Topics: Administration, Oral; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Depression, Chemical; Dose-Response Relationship, Drug; Forearm; Humans; Imidazoles; Infusions, Intra-Arterial; Losartan; Male; Plethysmography; Tetrazoles; Vascular Resistance; Vasoconstrictor Agents | 1996 |
Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers.
Topics: Acrylates; Adult; Antifungal Agents; Antihypertensive Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Fluconazole; Humans; Imidazoles; Losartan; Male; Middle Aged; Reference Values; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Tetrazoles; Thiophenes; Time Factors | 1997 |
Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.
Topics: Adult; Antifungal Agents; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Double-Blind Method; Drug Interactions; Female; Fluconazole; Humans; Imidazoles; Itraconazole; Losartan; Male; Mixed Function Oxygenases; Reference Values; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Tetrazoles | 1998 |
A radioreceptor assay for the analysis of AT1-receptor antagonists. Correlation with complementary LC data reveals a potential contribution of active metabolites.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Proteins; Chromatography, High Pressure Liquid; Double-Blind Method; Humans; Imidazoles; Losartan; Male; Placebos; Pyrimidines; Radioligand Assay; Rats; Rats, Wistar; Receptors, Angiotensin; Reference Values; Sensitivity and Specificity; Tetrazoles | 1998 |
The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Blood Pressure; Diastole; Female; Half-Life; Humans; Imidazoles; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Systole; Tetrazoles | 2000 |
Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.
Topics: Adult; Anti-Arrhythmia Agents; Antihypertensive Agents; Area Under Curve; Beverages; Biological Availability; Chromatography, High Pressure Liquid; Citrus; Cross-Over Studies; Female; Half-Life; Humans; Imidazoles; Losartan; Male; Tetrazoles | 2001 |
Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
Topics: Administration, Oral; Adult; Alleles; Antihypertensive Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Female; Genotype; Humans; Imidazoles; Losartan; Male; Middle Aged; Pharmacogenetics; Spain; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Sweden; Tetrazoles | 2002 |
Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Arachidonic Acid; Biotransformation; Cells, Cultured; Cyclooxygenase 2; Dinoprost; Drug Design; Endothelium, Vascular; Enzyme Activation; Female; Humans; Hypertension; Imidazoles; Inflammation; Intercellular Adhesion Molecule-1; Isoenzymes; Lipopolysaccharides; Losartan; Male; Membrane Proteins; Middle Aged; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; RNA, Messenger; Tetrazoles; Thromboxane A2; Up-Regulation; Vasoconstrictor Agents | 2002 |
Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry.
Topics: Antihypertensive Agents; Child, Preschool; Chromatography, High Pressure Liquid; Humans; Imidazoles; Indicators and Reagents; Losartan; Mass Spectrometry; Quality Control; Reference Standards; Reproducibility of Results; Tetrazoles | 2003 |
Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.
Topics: Adult; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Blood Pressure; Cytochrome P-450 CYP2C9; Female; Genotype; Heart Rate; Humans; Imidazoles; Japan; Losartan; Male; Tetrazoles | 2003 |
Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diet, Sodium-Restricted; Drug Resistance; Female; Genotype; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Polymorphism, Genetic; Receptor, Angiotensin, Type 1; Sodium Chloride, Dietary; Tetrazoles; Vascular Resistance | 2005 |
Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Colorectal Neoplasms; Cytochrome P-450 CYP2C9; Female; Fluorouracil; Genotype; Humans; Imidazoles; Losartan; Male; Middle Aged; Oxidation-Reduction; Tetrazoles | 2006 |
The effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects.
Topics: Adsorption; Adult; Angiotensin II Type 1 Receptor Blockers; Carbon; Cross-Over Studies; Dietary Fats; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Female; Food-Drug Interactions; Gastrointestinal Agents; Humans; Imidazoles; Losartan; Male; Oxides; Tetrazoles; Time Factors | 2006 |
Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients.
Topics: Adolescent; Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C9; Drug Antagonism; Epilepsy; Female; Genotype; Humans; Imidazoles; Losartan; Male; Middle Aged; Polymerase Chain Reaction; Tetrazoles; Valproic Acid | 2007 |
The pharmacokinetics of losartan in renal insufficiency.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Blood Pressure; Creatinine; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Imidazoles; Losartan; Male; Middle Aged; Renal Insufficiency; Tetrazoles | 1995 |
Effect of soy extract administration on losartan pharmacokinetics in healthy female volunteers.
Topics: Anti-Arrhythmia Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; China; Chromatography, Liquid; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Female; Glycine max; Humans; Imidazoles; Losartan; Plant Extracts; Tandem Mass Spectrometry; Tetrazoles; Time Factors; Young Adult | 2009 |
Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Cell Movement; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Muscle Cells; PPAR gamma; Telmisartan; Tetrazoles | 2009 |
Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Matrix Metalloproteinase 9; Middle Aged; NADPH Oxidases; Oxidative Stress; Oxygen; Phagocytes; Protein Kinase C; Signal Transduction; Superoxides; Tetrazoles | 2009 |
Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Area Under Curve; Asian People; China; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Imidazoles; Losartan; Male; Tetrazoles; Tissue Distribution; Young Adult | 2012 |
Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C9; Genotype; Half-Life; Humans; Imidazoles; Losartan; Metabolic Clearance Rate; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Republic of Korea; Tetrazoles; Young Adult | 2012 |
Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Itraconazole; Losartan; Polypharmacy; Terfenadine | 2016 |
Serum Concentrations of Losartan Metabolites Correlate With Improved Physical Function in a Pilot Study of Prefrail Older Adults.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Frailty; Imidazoles; Losartan; Pilot Projects; Tetrazoles | 2022 |
Other Studies
186 other study(ies) available for exp3174 and losartan
| Article | Year |
|---|---|
Nonpeptide angiotensin II receptor antagonists: synthetic and computational chemistry of N-[[4-[2-(2H-tetrazol-5-yl)-1-cycloalken-1- yl]phenyl]methyl]imidazole derivatives and their in vitro activity.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Computer Simulation; Imidazoles; In Vitro Techniques; Losartan; Male; Models, Molecular; Rabbits; Rats; Rats, Inbred Strains; Tetrazoles | 1992 |
N-3-substituted pyrimidinones as potent, orally active, AT1 selective angiotensin II receptor antagonists.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Humans; Hypertension; Male; Models, Molecular; Molecular Conformation; Molecular Structure; Pyrimidinones; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiophenes | 1995 |
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Dogs; Imidazoles; Macaca mulatta; Pyridines; Rats | 1994 |
Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Indicators and Reagents; Kinetics; Magnetic Resonance Spectroscopy; Male; Mesencephalon; Molecular Structure; Muscle, Smooth, Vascular; Rabbits; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Structure-Activity Relationship; Sulfonamides; Triazoles | 1994 |
Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Blood Pressure; Carboxylic Acids; Chemical Phenomena; Chemistry, Physical; Imidazoles; Male; Molecular Structure; Pyrazoles; Rabbits; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 1993 |
Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.
Topics: Angiotensin II; Animals; Binding Sites; Male; Muscle, Smooth, Vascular; Rabbits; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Triazoles | 1993 |
Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoro
Topics: Angiotensin Receptor Antagonists; Animals; Aorta; Disease Models, Animal; GABA Antagonists; gamma-Aminobutyric Acid; Hypertension, Renal; Liver; Male; Muscle Contraction; Pyridines; Rabbits; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Structure-Activity Relationship | 1993 |
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Biological Availability; Iodine Radioisotopes; Liver; Male; Muscle Contraction; Niacin; Nicotinic Acids; Rabbits; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Receptors, Angiotensin; Tetrazoles | 1993 |
Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Binding, Competitive; Blood Pressure; Male; Molecular Structure; Rabbits; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Structure-Activity Relationship; Triazoles | 1993 |
Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
Topics: Acetylation; Adrenal Cortex; Amino Acid Sequence; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biological Availability; Cattle; Imidazoles; In Vitro Techniques; Kinetics; Male; Models, Molecular; Molecular Conformation; Molecular Sequence Data; Molecular Structure; Rats; Rats, Wistar; Receptors, Angiotensin; Structure-Activity Relationship | 1996 |
Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Pyrazoles; Rats; Structure-Activity Relationship; Tetrazoles | 1997 |
Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
Topics: Acrylates; Algorithms; Angiotensin II; Biphenyl Compounds; Databases, Factual; Imidazoles; Lactones; Losartan; Models, Molecular; Molecular Conformation; Pyridines; Quantitative Structure-Activity Relationship; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Sulfones; Tetrazoles; Thiophenes | 2003 |
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Binding Sites; Biphenyl Compounds; Kinetics; Losartan; Models, Molecular; Molecular Conformation; Oxidation-Reduction; Pharmaceutical Preparations; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Structure-Activity Relationship; Tetrazoles | 2005 |
New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Drug Design; Drug Evaluation, Preclinical; Hypertension; In Vitro Techniques; Losartan; Male; Molecular Structure; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Structure-Activity Relationship; Time Factors | 2006 |
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents | 2011 |
New losartan-hydrocaffeic acid hybrids as antihypertensive-antioxidant dual drugs: Ester, amide and amine linkers.
Topics: Amides; Amines; Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Aorta, Thoracic; Caffeic Acids; Cells, Cultured; Esters; Hypertension; Losartan; Male; Molecular Structure; Muscle, Smooth, Vascular; Rats; Rats, Wistar; Structure-Activity Relationship; Vasoconstrictor Agents | 2012 |
Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
Topics: Alleles; Angiotensin Receptor Antagonists; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Female; Half-Life; Humans; Male; Polymorphism, Genetic; Reference Values; Sex Factors | 2013 |
Effect of captopril and the nonpeptide angiotensin II antagonists, SK&F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis.
Topics: Acrylates; Angiotensin II; Animals; Blood Pressure; Captopril; Dogs; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Imidazoles; Inulin; Kidney; Losartan; Regional Blood Flow; Renal Artery Obstruction; Tetrazoles; Thiophenes | 1992 |
Blocking hypothalamic AT1 receptors lowers blood pressure in salt-sensitive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Anterior Hypothalamic Nucleus; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diet; Heart Rate; Imidazoles; Losartan; Microinjections; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sodium Chloride; Tetrazoles | 1992 |
Inhibition of the haemodynamic effects of angiotensin II in conscious rats by AT2-receptor antagonists given after the AT1-receptor antagonist, EXP 3174.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Heart Rate; Hemodynamics; Imidazoles; Losartan; Male; Pyridines; Rats; Regional Blood Flow; Tetrazoles | 1992 |
Inhibitory effects of DuP 753 and EXP3174 on responses to angiotensin II in pulmonary vascular bed of the cat.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Gas Analysis; Cats; Endothelins; Female; Hydrogen-Ion Concentration; Imidazoles; Losartan; Male; Norepinephrine; Pulmonary Circulation; Serotonin; Tetrazoles; Vasopressins | 1992 |
Effects of renin-angiotensin system blockade in guinea pigs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Pressure; Bradykinin; Cilazapril; Cyclooxygenase Inhibitors; Disease Models, Animal; Furosemide; Guinea Pigs; Hypertension; Imidazoles; Indomethacin; Losartan; Nephrectomy; Oligopeptides; Pyridazines; Renin; Renin-Angiotensin System; Tetrazoles | 1992 |
Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chromatography, High Pressure Liquid; Humans; Imidazoles; Losartan; Reproducibility of Results; Spectrophotometry, Ultraviolet; Tetrazoles | 1992 |
Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Binding Sites; Biphenyl Compounds; Female; Imidazoles; In Vitro Techniques; Iodine Radioisotopes; Kinetics; Losartan; Male; Muscle Contraction; Peptides; Rabbits; Rats; Rats, Inbred Strains; Receptors, Angiotensin; Tetrazoles | 1992 |
In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Binding, Competitive; Biphenyl Compounds; Brain; Cell Membrane; Culture Techniques; Humans; Imidazoles; Losartan; Macaca mulatta; Muscle, Smooth, Vascular; Rabbits; Rats; Species Specificity; Tetrazoles | 1992 |
In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Imidazoles; Injections, Intravenous; Losartan; Macaca mulatta; Male; Pressoreceptors; Pyridines; Rats; Rats, Inbred Strains; Tetrazoles | 1992 |
Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs.
Topics: Acrylates; Angiotensin I; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Dogs; Hemodynamics; Hypertension; Imidazoles; Losartan; Male; Rats; Rats, Inbred Strains; Tetrazoles; Thiophenes | 1992 |
Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Captopril; Dogs; Female; Furosemide; Imidazoles; Kidney; Kidney Function Tests; Losartan; Male; Pyridines; Radioimmunoassay; Renin-Angiotensin System; Tetrazoles | 1991 |
Effect of angiotensin II antagonism on canine renal sympathetic nerve function.
Topics: Angiotensin II; Animals; Blood Pressure; Captopril; Dogs; Electric Stimulation; Female; Imidazoles; Kidney; Losartan; Male; Norepinephrine; Pyridines; Saralasin; Sympathetic Nervous System; Tetrazoles; Vascular Resistance; Vasoconstriction | 1991 |
Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.
Topics: Administration, Oral; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Imidazoles; In Vitro Techniques; Losartan; Male; Rabbits; Rats; Rats, Inbred Strains; Receptors, Angiotensin; Tetrazoles | 1990 |
Angiotensin II is a potent stimulator of MAP-kinase activity in neonatal rat cardiac fibroblasts.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Becaplermin; Calcium-Calmodulin-Dependent Protein Kinases; Carbachol; Cell Division; Cells, Cultured; DNA; Enzyme Activation; Fibroblasts; Heart Ventricles; Imidazoles; Immunoblotting; Losartan; Myocardium; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Tetrazoles | 1995 |
The selective angiotensin AT1 receptor antagonist LR-B/081 potently inhibits drinking induced by central injection of angiotensin II in rats.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Carbachol; Dose-Response Relationship, Drug; Drinking; Eating; Imidazoles; Injections, Intraventricular; Lethal Dose 50; Losartan; Male; Milk; Pyrimidinones; Rats; Rats, Wistar; Renin-Angiotensin System; Tetrazoles; Thiophenes | 1995 |
Angiotensin II stimulates sis-inducing factor-like DNA binding activity. Evidence that the AT1A receptor activates transcription factor-Stat91 and/or a related protein.
Topics: Angiotensin II; Animals; Animals, Newborn; Base Sequence; Cells, Cultured; DNA-Binding Proteins; Gene Expression Regulation; Imidazoles; In Vitro Techniques; Losartan; Molecular Sequence Data; Myocardium; Nuclear Proteins; Phosphotyrosine; Promoter Regions, Genetic; Protein-Tyrosine Kinases; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Signal Transduction; STAT1 Transcription Factor; Tetrazoles; Trans-Activators; Transcription Factors; Transcription, Genetic; Tyrosine | 1994 |
Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension; Imidazoles; Injections, Intravenous; Injections, Intraventricular; Losartan; Male; Pyridazines; Pyridines; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Saralasin; Tetrazoles | 1995 |
Effect of acute and chronic treatment with the angiotensin II subtype 1 receptor antagonist EXP 3174 on baroreflex function in conscious spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Baroreflex; Blood Pressure; Heart Rate; Hypertension; Imidazoles; Losartan; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Angiotensin; Tetrazoles | 1995 |
Stable expression of a functional rat angiotensin II (AT1A) receptor in CHO-K1 cells: rapid desensitization by angiotensin II.
Topics: Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Base Sequence; Calcium; Cell Membrane; CHO Cells; Concanavalin A; Cricetinae; Gene Expression; Guanosine Triphosphate; Imidazoles; Losartan; Membrane Potentials; Molecular Sequence Data; Pyridines; Rats; Receptors, Angiotensin; Tetradecanoylphorbol Acetate; Tetrazoles; Transfection; Verapamil | 1995 |
Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Proteins; Humans; Imidazoles; Losartan; Protein Binding; Receptors, Angiotensin; Tetrazoles | 1995 |
Central administration of PD 123319 or EXP-3174 inhibits effects of angiotensin II.
Topics: Angiotensin II; Animals; Brain; Hemodynamics; Imidazoles; Injections, Intraventricular; Losartan; Male; Pyridines; Rats; Rats, Inbred Strains; Substance P; Tetrazoles | 1993 |
Systemic and coronary effects of the angiotensin II receptor antagonist EXP3174 in dogs.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Coronary Circulation; Dogs; Enalaprilat; Female; Furosemide; Hemodynamics; Imidazoles; Losartan; Male; Renin-Angiotensin System; Tetrazoles | 1993 |
Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antibody Specificity; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; B-Lymphocytes; Biotransformation; Biphenyl Compounds; Cell Line; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Imidazoles; Isoenzymes; Losartan; Male; Microsomes, Liver; NAD; NADP; Oxidation-Reduction; Oxidoreductases, N-Demethylating; Oxygen Isotopes; Recombinant Proteins; Spectrophotometry, Ultraviolet; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Subcellular Fractions; Tetrazoles | 1995 |
Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzoflavones; Biotransformation; Biphenyl Compounds; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Imidazoles; Losartan; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Receptors, Angiotensin; Tetrazoles | 1995 |
Cerebroventricular injection of angiotensin II antagonist: effects on blood pressure responses to central and systemic angiotensin II.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Imidazoles; Injections, Intraventricular; Losartan; Male; Microinjections; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Tetrazoles | 1995 |
Pharmacological profile of ME3221, a novel angiotensin II receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Biphenyl Compounds; Blood Pressure; Bradykinin; Callithrix; Disease Models, Animal; Drug Evaluation; Female; Femoral Artery; Heart Rate; Hypertension, Renal; Imidazoles; Losartan; Male; Rabbits; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Species Specificity; Tetrazoles | 1995 |
BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.
Topics: Adrenal Cortex; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Extracellular Space; Imidazoles; In Vitro Techniques; Losartan; Male; Membranes; Muscle Contraction; Muscle, Smooth, Vascular; Phosphatidylinositols; Rabbits; Rats; Tetrazoles | 1994 |
Effect of EXP 3174 on blood pressure of normoreninemic renal hypertensive rats.
Topics: Angiotensinogen; Animals; Antihypertensive Agents; Arteries; Blood Pressure; Hypertension, Renal; Imidazoles; Injections, Intravenous; Injections, Intraventricular; Losartan; Male; Rats; Rats, Wistar; Renin; Tetrazoles | 1995 |
Pharmacological studies of stonefish (Synanceja trachynis) venom.
Topics: Animals; Biphenyl Compounds; Blood Pressure; Captopril; Chromones; Dose-Response Relationship, Drug; Fish Venoms; Fishes; Guinea Pigs; Heptanoic Acids; Histamine; Ileum; Imidazoles; In Vitro Techniques; Indomethacin; Losartan; Male; Mecamylamine; Muscle Contraction; Muscle, Smooth; Phospholipases A; Phospholipases A2; Quinacrine; Rats; Receptors, Thromboxane; Serotonin; SRS-A; Tetrazoles; Vas Deferens | 1994 |
Effects of angiotensin II AT1- or AT2-receptor antagonists on drinking evoked by angiotensin II or water deprivation in rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Drinking; Heart Rate; Imidazoles; Injections, Intraventricular; Losartan; Male; Pyridines; Rats; Rats, Brattleboro; Tetrazoles; Water Deprivation | 1994 |
Novel angiotensin receptor subtypes in fowl.
Topics: Acetylcholine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Abdominal; Biphenyl Compounds; Blood Pressure; Cell Membrane; Chickens; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Imidazoles; In Vitro Techniques; Kinetics; Losartan; Models, Cardiovascular; Muscle Contraction; Muscle, Smooth, Vascular; Pyridines; Receptors, Angiotensin; Reserpine; Tetrazoles | 1994 |
Inhibitory effect of the nonpeptide angiotensin II receptor antagonist losartan and its active metabolite, E-3174, on cAMP phosphodiesterase: additional action of the antagonists.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Brain; Cattle; Imidazoles; Losartan; Tetrazoles | 1994 |
Differential regulation of angiotensin II and losartan binding sites in glomeruli and mesangial cells.
Topics: Administration, Oral; Angiotensin II; Animals; Binding Sites; Biphenyl Compounds; Glomerular Mesangium; Imidazoles; In Vitro Techniques; Kidney Glomerulus; Losartan; Male; Rats; Rats, Wistar; Receptors, Angiotensin; RNA, Messenger; Saralasin; Tetrazoles | 1994 |
Immunological reactivity of angiotensin II receptor antagonists: possible implications for receptor binding sites.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antibodies, Monoclonal; Antihypertensive Agents; Biphenyl Compounds; Imidazoles; In Vitro Techniques; Indicators and Reagents; Iodine Radioisotopes; Losartan; Molecular Conformation; Oligopeptides; Pyridines; Rats; Receptors, Angiotensin; Saralasin; Tetrazoles | 1993 |
Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.
Topics: Anesthesia; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Coronary Circulation; Disease Models, Animal; Dogs; Enalaprilat; Female; Furosemide; Heart Rate; Imidazoles; Injections, Intravenous; Losartan; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Renin-Angiotensin System; Tetrazoles | 1993 |
Effects of EXP3174, a non-peptide angiotensin II receptor antagonist, on renal hemodynamics and renal function in dogs.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Water; Dogs; Glomerular Filtration Rate; Heart Rate; Imidazoles; Infusions, Intra-Arterial; Kidney; Kidney Function Tests; Losartan; Renal Circulation; Sodium; Tetrazoles | 1993 |
Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethy
Topics: Adrenal Cortex; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cattle; Imidazoles; In Vitro Techniques; Iodine Radioisotopes; Kinetics; Losartan; Male; Muscle Contraction; Muscle, Smooth, Vascular; Prodrugs; Protein Binding; Rabbits; Rats; Rats, Sprague-Dawley; Substrate Specificity; Tetrazoles | 1993 |
Differential blockade of central effects of angiotensin II by AT2-receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Brain; Cardiovascular System; Imidazoles; Injections, Intraventricular; Losartan; Male; Pyridines; Rats; Tetrazoles | 1993 |
EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Cells, Cultured; Female; Imidazoles; In Vitro Techniques; Losartan; Muscle, Smooth, Vascular; Rats; Rats, Inbred WKY; RNA, Messenger; Tetrazoles | 1993 |
Analysis of the inhibitory effects of DuP 753 and EXP 3174 on responses to angiotensin II in the feline hindquarters vascular bed.
Topics: Angiotensin II; Angiotensin III; Animals; Biphenyl Compounds; Blood Pressure; Cats; Dose-Response Relationship, Drug; Female; Imidazoles; Losartan; Male; Perfusion; Tetrazoles | 1993 |
Comparison of the regional haemodynamic effects of the AT1-receptor antagonists, losartan and EXP 3174, in water-deprived Brattleboro rats.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Hemodynamics; Imidazoles; Losartan; Male; Rats; Rats, Brattleboro; Regional Blood Flow; Tetrazoles; Time Factors; Water Deprivation | 1993 |
Intrinsic properties of the nonpeptide angiotensin II antagonist losartan in glomeruli and mesangial cells at high concentrations.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Calcium; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Glomerular Mesangium; Humans; Imidazoles; Kidney Glomerulus; Losartan; Male; Rats; Rats, Sprague-Dawley; Tetrazoles; Vasoconstrictor Agents | 1993 |
Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biological Transport; Biphenyl Compounds; Carbon Radioisotopes; Hydrogen-Ion Concentration; Imidazoles; Kidney; Kinetics; Losartan; Male; Microvilli; Naphthalenes; Rats; Rats, Sprague-Dawley; Tetrazoles; Thiophenes; Uric Acid | 1996 |
Angiotensin type 1 receptor antagonists CV-11974 and EXP 3174 cause selective renal vasodilatation in conscious spontaneously hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Imidazoles; Losartan; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Circulation; Tetrazoles; Vasodilation | 1996 |
Functional evidence for the ability of angiotensin AT1 receptor antagonists to cross the blood-brain barrier in rats.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood-Brain Barrier; Carbachol; Dose-Response Relationship, Drug; Drinking; Imidazoles; Injections, Intraperitoneal; Injections, Intraventricular; Losartan; Male; Nicotinic Acids; Pyrimidinones; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Thiophenes | 1996 |
Threshold sodium excretory and renal blood flow effects of angiotensin converting enzyme inhibition.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Differential Threshold; Diuresis; Hemodynamics; Imidazoles; Losartan; Natriuresis; Nephrectomy; Potassium; Ramipril; Rats; Rats, Wistar; Renal Circulation; Tetrazoles; Vasodilation | 1995 |
Interactions of nonpeptide angiotensin II receptor antagonists at imidazoline/guanidinium receptor sites in rat forebrain.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Autoradiography; Biphenyl Compounds; Imidazoles; Losartan; Prosencephalon; Rats; Rats, Sprague-Dawley; Tetrazoles | 1996 |
Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Half-Life; Imidazoles; Injections, Intravenous; Lethal Dose 50; Losartan; Male; Rats; Rats, Sprague-Dawley; Tetrazoles | 1996 |
The active state of the AT1 angiotensin receptor is generated by angiotensin II induction.
Topics: Amino Acid Sequence; Angiotensin II; Animals; Binding Sites; COS Cells; Imidazoles; Kinetics; Losartan; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Protein Conformation; Protein Structure, Secondary; Rats; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Transfection | 1996 |
HR 720, a novel angiotensin receptor antagonist inhibits the angiotensin II-induced trophic effects, fibronectin release and fibronectin-EIIIA+ expression in rat aortic vascular smooth muscle cells in vitro.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Biphenyl Compounds; Cells, Cultured; Fibronectins; Imidazoles; Leucine; Losartan; Male; Muscle, Smooth, Vascular; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tetrazoles | 1997 |
In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Carotid Arteries; Carotid Artery Injuries; Catheterization; Cell Division; Imidazoles; In Vitro Techniques; Losartan; Muscle Proteins; Muscle, Smooth, Vascular; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Wistar; Stimulation, Chemical; Tetrazoles | 1997 |
The pharmacologic profile of 606A, a novel angiotensin II receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cattle; Dogs; Female; Guinea Pigs; Imidazoles; Losartan; Male; Rabbits; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Tetrazoles; Vasoconstriction | 1997 |
Regulation of angiotensin II receptor AT1 subtypes in renal afferent arterioles during chronic changes in sodium diet.
Topics: Actins; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Compounds; Cloning, Molecular; Culture Techniques; DNA, Complementary; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enalaprilat; Gene Expression Regulation; Imidazoles; Kidney; Losartan; Male; Oligopeptides; Polymerase Chain Reaction; Pyridines; Rats; Rats, Wistar; Receptors, Angiotensin; Renal Artery; Renal Circulation; Ribonucleases; RNA, Messenger; Sodium, Dietary; Tetrazoles; Vasoconstrictor Agents | 1997 |
In vivo angiotensin II receptor blockade and converting enzyme inhibition on canine aortic viscoelasticity.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Dogs; Elasticity; Enalaprilat; Hypertension, Renovascular; Imidazoles; Losartan; Male; Reference Values; Tetrazoles; Viscosity | 1997 |
Angiotensin receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Losartan; Scleroderma, Systemic; Tetrazoles | 1997 |
An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Chromatography, High Pressure Liquid; Humans; Imidazoles; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Tetrazoles | 1997 |
The type I angiotensin II receptor couples to Stat1 and Stat3 activation through Jak2 kinase in neonatal rat cardiac myocytes.
Topics: Angiotensin II; Animals; Animals, Newborn; Cells, Cultured; DNA-Binding Proteins; Heart; Imidazoles; Janus Kinase 2; Losartan; Myocardium; Nitriles; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; STAT1 Transcription Factor; STAT3 Transcription Factor; Tetrazoles; Trans-Activators; Transcription, Genetic; Tyrosine; Tyrphostins | 1997 |
Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Azoles; Binding, Competitive; Biphenyl Compounds; Blood Pressure; Cattle; Decerebrate State; Imidazoles; In Vitro Techniques; Losartan; Male; Muscle, Smooth, Vascular; Pyridines; Rabbits; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles | 1997 |
Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model.
Topics: Angiotensin II; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Area Under Curve; Blood Pressure; Disease Models, Animal; Half-Life; Hypertension; Imidazoles; Infusions, Intravenous; Losartan; Receptors, Angiotensin; Swine; Tetrazoles | 1997 |
Effect of PD 123319, an AT-2 antagonist, on renal function of the anesthetized dog: comparison with EXP 3174, an AT-1 blocker.
Topics: Angiotensin Receptor Antagonists; Animals; Diuresis; Dogs; Drug Combinations; Glomerular Filtration Rate; Imidazoles; Injections, Intra-Arterial; Kidney; Losartan; Male; Natriuresis; Pyridines; Renal Circulation; Tetrazoles | 1997 |
Comparative effects of the angiotensin II receptor blocker EXP 3174 and of the angiotensin-converting enzyme inhibitor captopril on renal glomerular hemodynamics in the dog.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Flow Velocity; Blood Pressure; Bradykinin; Captopril; Dogs; Drug Combinations; Female; Glomerular Filtration Rate; Imidazoles; Kidney Glomerulus; Losartan; Male; Potassium; Sodium; Tetrazoles; Urea; Vascular Resistance; Vasodilation; Water | 1997 |
Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart.
Topics: Angiotensin Receptor Antagonists; Animals; Enalaprilat; Hemodynamics; Imidazoles; Losartan; Male; Myocardial Infarction; Myocardium; Swine; Tetrazoles | 1997 |
Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate.
Topics: Antihypertensive Agents; Chromatography, High Pressure Liquid; Dialysis Solutions; Humans; Imidazoles; Kidney Failure, Chronic; Losartan; Peritoneal Dialysis, Continuous Ambulatory; Sensitivity and Specificity; Tetrazoles | 1997 |
The in vitro pharmacological profile of KR31080, a nonpeptide AT1 receptor antagonist.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Cattle; Cerebellum; Humans; Imidazoles; In Vitro Techniques; Iodine Radioisotopes; Losartan; Membranes; Muscle Contraction; Muscle, Smooth, Vascular; Pyridines; Rabbits; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Recombinant Proteins; Tetrazoles | 1998 |
Role of nitric oxide in responses to renin-angiotensin system inhibition in sodium-depleted guinea pig and rat.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Dipeptides; Guinea Pigs; Imidazoles; Losartan; Male; Morpholines; Nitric Oxide; Nitric Oxide Synthase; Nitroarginine; Rats; Rats, Sprague-Dawley; Renin; Renin-Angiotensin System; Sodium; Tetrazoles | 1998 |
HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Chromatography, High Pressure Liquid; Humans; Imidazoles; Losartan; Rats; Receptors, Angiotensin; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tetrazoles; Tissue Distribution | 1998 |
Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers.
Topics: Adult; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antihypertensive Agents; Drug Interactions; Erythromycin; Female; Humans; Imidazoles; Losartan; Male; Reference Values; Rifampin; Tetrazoles; Time Factors | 1998 |
Receptor occupancy in myocardium, adrenal cortex, and brain by TH-142177, a novel AT1 receptor antagonist in rats, in relation to its plasma concentration and hypotensive effect.
Topics: Adrenal Cortex; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Brain; Glycine; Imidazoles; Losartan; Male; Myocardium; Radioligand Assay; Rats; Rats, Wistar; Receptors, Angiotensin; Tetrazoles | 1998 |
Studies on nonpeptide angiotensin II receptor antagonists. IV. Synthesis and biological evaluation of 4-acrylamide-1H-imidazole derivatives.
Topics: Acrylamides; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Diet, Sodium-Restricted; Disease Models, Animal; Diuretics; Dogs; Female; Furosemide; Hypertension; Imidazoles; Losartan; Male; Prodrugs; Rabbits; Rats; Rats, Wistar; Structure-Activity Relationship; Tetrazoles | 1998 |
Thrombin receptor expression is increased by angiotensin II in cultured and native vascular smooth muscle cells.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Blotting, Northern; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Imidazoles; In Vitro Techniques; Indoles; Losartan; Male; Muscle Contraction; Muscle, Smooth, Vascular; Polymerase Chain Reaction; Protein Kinase C; Rats; Rats, Wistar; Receptors, Thrombin; RNA, Messenger; Tetrazoles; Thrombin | 1998 |
Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Angiotensin II; Animals; Antihypertensive Agents; Aorta; Endothelins; Endothelium, Vascular; Imidazoles; Losartan; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Inbred SHR; Receptors, Prostaglandin; Receptors, Thromboxane A2, Prostaglandin H2; Tetrazoles; Thromboxane A2; Vasoconstriction; Vasoconstrictor Agents | 1998 |
Losartan antagonism of angiotensin-II-induced potassium secretion across rat colon.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biological Transport; Colon; Dose-Response Relationship, Drug; Drug Antagonism; Extracellular Space; Hydrolysis; Imidazoles; In Vitro Techniques; Losartan; Male; Potassium; Pyridines; Rats; Rats, Sprague-Dawley; Rubidium Radioisotopes; Tetrazoles | 1998 |
Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Area Under Curve; Blood Glucose; Blood Proteins; Diabetes Mellitus, Experimental; Half-Life; Imidazoles; Injections, Intravenous; Losartan; Metabolic Clearance Rate; Rats; Rats, Sprague-Dawley; Tetrazoles | 1998 |
Effects of BAY 10-6734 (Embusartan), a new angiotensin II type I receptor antagonist, on vascular smooth muscle cell growth.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Calcium; Cell Division; Cells, Cultured; Cytosol; Dihydropyridines; DNA; Imidazoles; Losartan; Male; Muscle, Smooth, Vascular; Protein Biosynthesis; Radioligand Assay; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Species Specificity; Tetrazoles | 1999 |
Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174.
Topics: Adult; Alleles; Anti-Arrhythmia Agents; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Genotype; Humans; Imidazoles; Losartan; Male; Mixed Function Oxygenases; Phenotype; Reference Values; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Tetrazoles; Volunteers | 1999 |
Effects of angiotensin II receptor blockade on proximal fluid uptake in the rat kidney.
Topics: Absorption; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Body Fluids; Dose-Response Relationship, Drug; Imidazoles; Kidney Tubules, Proximal; Losartan; Male; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles | 1999 |
Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Differential acute effects according to the renin-angiotensin system activation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Dogs; Enalaprilat; Female; Heart Failure; Hemodynamics; Imidazoles; Losartan; Male; Renin; Renin-Angiotensin System; Tetrazoles; Vasodilation | 1999 |
Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Proteins; Female; Humans; Imidazoles; In Vitro Techniques; Irbesartan; Kinetics; Losartan; Male; Muscle Contraction; Muscle, Smooth, Vascular; Portal Vein; Rabbits; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles | 1999 |
Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Binding, Competitive; Biphenyl Compounds; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Recombinant Proteins; Tetrazoles | 1999 |
Interaction of the autonomic nervous and the renin-angiotensin system in heart and kidney.
Topics: Angiotensin II; Autonomic Nervous System; Heart; Humans; Imidazoles; Kidney; Losartan; Norepinephrine; Renin-Angiotensin System; Tetrazoles | 1999 |
Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Arteries; Benzimidazoles; Biphenyl Compounds; Endothelium, Vascular; Humans; Imidazoles; Losartan; Muscle Tonus; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Vasoconstrictor Agents | 1999 |
EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction.
Topics: Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Captopril; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Female; Heart Ventricles; Humans; Imidazoles; Losartan; Male; Myocardial Infarction; Myocardial Ischemia; Tetrazoles; Time Factors | 1999 |
Diverse effects of AT1 receptor antagonists on normal blood pressure and regulatory system.
Topics: Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Blood Pressure; Heart Rate; Imidazoles; Losartan; Male; Pressoreceptors; Propranolol; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Glutamate; Reflex; Tetrazoles | 1999 |
Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Cell Division; Coronary Disease; Coronary Vessels; Culture Techniques; Imidazoles; Losartan; Muscle, Smooth, Vascular; Pyridines; Recurrence; Swine; Tetrazoles | 1999 |
Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Dogs; Dose-Response Relationship, Drug; Hypertension, Renal; Hypotension, Orthostatic; Imidazoles; Losartan; Male; Prodrugs; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Species Specificity; Tetrazoles | 1999 |
Method for the simultaneous determination of losartan and its major metabolite, EXP-3174, in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry.
Topics: Antihypertensive Agents; Chromatography, Liquid; Drug Stability; Humans; Imidazoles; Losartan; Mass Spectrometry; Quality Control; Sensitivity and Specificity; Tetrazoles | 1999 |
Effects of angiotensin II and antagonists on AT(1) receptor expression in mesangial cells.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Dexamethasone; Dose-Response Relationship, Drug; Gene Expression Regulation; Glomerular Mesangium; Imidazoles; Losartan; Male; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Tetrazoles | 1999 |
Inhibitory effect of KT3-671, a non-peptide angiotensin subtype 1 receptor antagonist, on sympathetic neurotransmission in isolated rabbit aorta.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Imidazoles; In Vitro Techniques; Losartan; Male; Norepinephrine; Rabbits; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Sympathetic Nervous System; Synaptic Transmission; Tetrazoles; Tritium | 2000 |
Losartan and its metabolite E3174 modify cardiac delayed rectifier K(+) currents.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; Heart; Heart Ventricles; Humans; Imidazoles; In Vitro Techniques; Kv1.5 Potassium Channel; Losartan; Potassium Channels; Potassium Channels, Voltage-Gated; Tetrazoles; Time Factors; Trans-Activators; Transcriptional Regulator ERG; Ventricular Function | 2000 |
Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers.
Topics: 2,4-Dinitrophenol; Angiotensin II; Animals; Anti-Arrhythmia Agents; Antimetabolites; Biological Transport, Active; Caco-2 Cells; Cell Line; Chromatography, Liquid; Dogs; Energy Metabolism; Epithelium; Humans; Imidazoles; Kidney; Kinetics; LLC-PK1 Cells; Losartan; Mass Spectrometry; Multidrug Resistance-Associated Protein 2; Swine; Temperature; Tetrazoles | 2000 |
[Effect of losartan on human platelet activation by thromboxane A2].
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adult; Angiotensin II; Humans; Imidazoles; Losartan; Male; Platelet Activation; Receptors, Thromboxane; Tetrazoles; Thromboxane A2 | 2000 |
Effect of intrarenal infusion of angiotensin-(1-7) in the dog.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Diuresis; Dogs; Female; Glomerular Filtration Rate; Imidazoles; Infusions, Intra-Arterial; Kidney; Losartan; Male; Peptide Fragments; Receptors, Angiotensin; Renal Artery; Renal Circulation; Tetrazoles; Urodynamics; Vasodilator Agents | 2000 |
Evidence that nitric oxide regulates AT1-receptor agonist and antagonist efficacy in rat injured carotid artery.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Carotid Arteries; Carotid Artery Injuries; Endothelium, Vascular; Enzyme Inhibitors; Imidazoles; Losartan; Male; Nitric Oxide; omega-N-Methylarginine; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Vasoconstriction | 2000 |
Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antibodies, Monoclonal; Benzimidazoles; Benzoates; Binding, Competitive; Biphenyl Compounds; Blood Platelets; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Platelet Activation; Pyridines; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Telmisartan; Tetrazoles; Thromboxane A2; Time Factors; Valine; Valsartan | 2000 |
Angiotensin-converting enzyme-independent angiotensin formation in a human model of myocardial ischemia: modulation of norepinephrine release by angiotensin type 1 and angiotensin type 2 receptors.
Topics: Aged; Angiotensin II; Chymases; Female; Humans; Imidazoles; Losartan; Male; Middle Aged; Myocardial Ischemia; Norepinephrine; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Serine Endopeptidases; Tetrazoles | 2000 |
In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Imidazoles; Kidney; Losartan; Male; Membranes; Osmolar Concentration; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Tetrazoles | 2000 |
Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection.
Topics: Antihypertensive Agents; Chromatography, High Pressure Liquid; Humans; Hypertension; Imidazoles; Losartan; Tetrazoles | 2000 |
The effects of peptide and nonpeptide angiotensin II-receptor ligands on the activity of brain monoamine oxidase in water-repleted rats.
Topics: Angiotensin II; Animals; Body Water; Brain; Drinking; Imidazoles; Isoenzymes; Ligands; Losartan; Male; Monoamine Oxidase; Peptides; Rats; Rats, Wistar; Receptors, Angiotensin; Tetrazoles | 2000 |
Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition.
Topics: Antihypertensive Agents; Blood Platelets; Collagen; Humans; Imidazoles; Losartan; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Thromboxane; Tetrazoles; Thromboxane-A Synthase; Valine; Valsartan | 2000 |
Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cardiovascular System; Dogs; Echocardiography; Electric Stimulation; Enalapril; Heart Failure; Hemodynamics; Hormones; Imidazoles; Losartan; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; Renin-Angiotensin System; Tachycardia; Tetrazoles; Ventricular Function | 2001 |
CoenzymeA glutathione disulfide is a potent modulator of angiotensin II-induced vasoconstriction.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Coenzyme A; Dose-Response Relationship, Drug; Imidazoles; In Vitro Techniques; Losartan; Male; Perfusion; Rats; Rats, Inbred WKY; Tetrazoles; Time Factors; Vasoconstriction; Vasomotor System | 2001 |
Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling.
Topics: Angiotensin Receptor Antagonists; Animals; Arachidonic Acids; Benzimidazoles; Biphenyl Compounds; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Imidazoles; Losartan; Phospholipases A; Phospholipases A2; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Thromboxane; Renin-Angiotensin System; Signal Transduction; Tetrazoles; Thromboxane A2 | 2001 |
Paeoniae Radix, a traditional Chinese medicine, and CYP2C9 activity.
Topics: Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Imidazoles; Losartan; Medicine, Chinese Traditional; Paeonia; Phytotherapy; Plant Preparations; Tetrazoles | 2002 |
Ischemia promotes renin activation and angiotensin formation in sympathetic nerve terminals isolated from the human heart: contribution to carrier-mediated norepinephrine release.
Topics: Angiotensin II; Antihypertensive Agents; Female; Heart Atria; Heart Conduction System; Humans; Imidazoles; In Vitro Techniques; Losartan; Male; Middle Aged; Myocardial Ischemia; Norepinephrine; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Renin; Sympathetic Nervous System; Synaptosomes; Tetrazoles | 2002 |
Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release.
Topics: Angiotensin Receptor Antagonists; Blood Platelets; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Imidazoles; Kinetics; Losartan; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2002 |
Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7).
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Epoprostenol; Fibrinolytic Agents; Hypertension, Renal; Imidazoles; Infusions, Intravenous; Losartan; Male; Nitric Oxide; Nitric Oxide Synthase; Peptide Fragments; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Venous Thrombosis | 2002 |
Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Base Sequence; Benzimidazoles; Biphenyl Compounds; Coronary Vessels; Culture Techniques; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Losartan; Male; Middle Aged; Molecular Sequence Data; Probability; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Valine; Valsartan; Vasoconstriction | 2002 |
AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium.
Topics: Angiotensin I; Animals; Binding, Competitive; Cattle; Cells, Cultured; Cricetinae; Electrochemistry; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Humans; Imidazoles; Losartan; Molecular Mimicry; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Peptide Fragments; Pyridines; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Substrate Specificity; Superoxides; Tetrazoles | 2002 |
Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Chlorocebus aethiops; COS Cells; Dose-Response Relationship, Drug; Humans; Imidazoles; In Vitro Techniques; Liver; Losartan; Membranes; Oligopeptides; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Thiadiazoles; Time Factors; Transfection | 2002 |
Functional antagonism of different angiotensin II type I receptor blockers in human arteries.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Dose-Response Relationship, Drug; Humans; Imidazoles; In Vitro Techniques; Losartan; Mammary Arteries; Muscle Contraction; Muscle, Smooth, Vascular; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2002 |
Peptide and nonpeptide antagonist interaction with constitutively active human AT1 receptors.
Topics: Alanine; Amino Acid Substitution; Animals; Antihypertensive Agents; Aspartic Acid; Benzimidazoles; Biphenyl Compounds; CHO Cells; Cricetinae; Humans; Imidazoles; Kinetics; Losartan; Mutagenesis, Site-Directed; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Transfection; Tritium | 2003 |
A two-state model of antagonist-AT1 receptor interaction: further support by binding studies at low temperature.
Topics: Angiotensin Receptor Antagonists; Animals; Binding Sites; Biphenyl Compounds; CHO Cells; Cold Temperature; Computer Simulation; Cricetinae; Imidazoles; Irbesartan; Kinetics; Losartan; Models, Biological; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Recombinant Proteins; Tetrazoles; Thermodynamics; Transfection | 2003 |
Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.
Topics: Adolescent; Adult; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Female; Genotype; Half-Life; Humans; Imidazoles; Inactivation, Metabolic; Losartan; Male; Tetrazoles | 2003 |
Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Antagonism; Humans; Imidazoles; In Vitro Techniques; Irbesartan; Losartan; Muscle Contraction; Muscle, Smooth, Vascular; Receptors, Thromboxane A2, Prostaglandin H2; Saphenous Vein; Tetrazoles; Valine; Valsartan | 2003 |
The effects of peptide and nonpeptide antagonists of angiotensin II receptors on the noradrenaline uptake of different brain structures in rats with angiotensin II-induced increase of water intake.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Brain; Drinking Behavior; Imidazoles; Losartan; Male; Norepinephrine; Rats; Rats, Wistar; Saralasin; Tetrazoles | 2003 |
Relative roles of nitric oxide, prostanoids and angiotensin II in the regulation of canine glomerular hemodynamics. A micropuncture study.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cyclooxygenase Inhibitors; Dogs; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Hemodynamics; Imidazoles; Indomethacin; Kidney Glomerulus; Losartan; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Prostaglandins; Renal Circulation; Tetrazoles; Time Factors | 2004 |
[Dosage equivalents of AT1-receptor antagonists available in Germany].
Topics: Acrylates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Germany; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Placebos; Telmisartan; Tetrazoles; Therapeutic Equivalency; Thiophenes; Time Factors; Valine; Valsartan | 2003 |
Nitric oxide-dependent antiplatelet action of AT1-receptor antagonists in a pulmonary thromboembolism in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Imidazoles; Injections, Intraperitoneal; Losartan; Mice; Platelet Aggregation Inhibitors; Pulmonary Embolism; Rats; Tetrazoles; Valine; Valsartan | 2003 |
"Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists.
Topics: Amino Acid Sequence; Animals; Benzimidazoles; Binding, Competitive; Biphenyl Compounds; Cell Membrane; COS Cells; Dose-Response Relationship, Drug; Imidazoles; Kinetics; Ligands; Losartan; Models, Chemical; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Peptides; Protein Conformation; Rats; Receptor, Angiotensin, Type 1; Temperature; Tetrazoles; Time Factors | 2004 |
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Cell Differentiation; Cells, Cultured; Chlorocebus aethiops; Drug Evaluation, Preclinical; Gene Expression Regulation; Imidazoles; Insulin; Irbesartan; Losartan; Male; Mice; Models, Molecular; Myoblasts; Protein Conformation; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Telmisartan; Tetrazoles; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Triglycerides; Valine; Valsartan; Weight Gain | 2004 |
Down-regulation of inositol 1,4,5-trisphosphate receptor in cells stably expressing the constitutively active angiotensin II N111G-AT(1) receptor.
Topics: Angiotensin II; Antihypertensive Agents; Calcium; Calcium Channels; Calcium Signaling; Cell Line; Down-Regulation; Embryo, Mammalian; Humans; Imidazoles; Inositol 1,4,5-Trisphosphate; Inositol 1,4,5-Trisphosphate Receptors; Kidney; Losartan; Receptor, Angiotensin, Type 1; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Tetrazoles; Thapsigargin | 2004 |
Angiotensin II receptor modulation of renal vascular resistance and neurotransmission in young and adult spontaneously hypertensive rats.
Topics: Aging; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Imidazoles; Kidney; Losartan; Male; Norepinephrine; Pyridines; Rats; Rats, Inbred SHR; Rats, Inbred WF; Receptor, Angiotensin, Type 1; Signal Transduction; Sympathetic Nervous System; Tetrazoles; Vascular Resistance; Vasoconstrictor Agents | 2005 |
The constitutively active N111G-AT1 receptor for angiotensin II modifies the morphology and cytoskeletal organization of HEK-293 cells.
Topics: Angiotensin II; Cell Line; Cell Shape; Cytoskeleton; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Losartan; Mutation; Phenotype; Protein Serine-Threonine Kinases; Receptor, Angiotensin, Type 1; rho-Associated Kinases; Tetrazoles | 2005 |
A116C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension.
Topics: Adenine; Alleles; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cytosine; Heart Rate; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Losartan; Polymorphism, Genetic; Receptor, Angiotensin, Type 1; Tetrazoles | 2005 |
Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites.
Topics: 3T3-L1 Cells; Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Differentiation; Chlorocebus aethiops; COS Cells; Gene Expression; Imidazoles; Ligands; Losartan; Mice; PPAR gamma; Protein Structure, Tertiary; RNA, Messenger; Tetrazoles | 2006 |
Proposal of a new binding orientation for non-peptide AT1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis.
Topics: Amino Acid Sequence; Angiotensin II Type 1 Receptor Blockers; Animals; Cattle; Crystallography, X-Ray; Imidazoles; Lipid Bilayers; Losartan; Models, Molecular; Molecular Sequence Data; Mutation; Phospholipids; Quantitative Structure-Activity Relationship; Receptor, Angiotensin, Type 1; Rhodopsin; Sequence Homology, Amino Acid; Tetrazoles | 2006 |
Simultaneous determination of losartan, EXP-3174 and hydrochlorothiazide in plasma via fully automated 96-well-format-based solid-phase extraction and liquid chromatography-negative electrospray tandem mass spectrometry.
Topics: Antihypertensive Agents; Chemical Fractionation; Drug Combinations; Drug Monitoring; Humans; Hydrochlorothiazide; Imidazoles; Losartan; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tetrazoles | 2007 |
Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4.
Topics: Acetates; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biological Transport; Biphenyl Compounds; Blotting, Western; Cell Line; Chromones; Cyclopropanes; Dose-Response Relationship, Drug; Estrone; Humans; Imidazoles; Indoles; Leukotriene Antagonists; Losartan; Molecular Structure; Organic Anion Transporters, Sodium-Independent; Phenylcarbamates; Quinolines; Structure-Activity Relationship; Sulfides; Sulfonamides; Tetrazoles; Tosyl Compounds; Transfection; Tritium; Valine; Valsartan | 2006 |
Angiotensin receptor type 1 blockade in astroglia decreases hypoxia-induced cell damage and TNF alpha release.
Topics: Animals; Astrocytes; Cell Hypoxia; Cells, Cultured; Imidazoles; Losartan; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Tumor Necrosis Factor-alpha | 2007 |
Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.
Topics: Administration, Oral; Alleles; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C9; Gene Frequency; Humans; Imidazoles; Losartan; Male; Tetrazoles; Young Adult | 2009 |
Rapid determination of losartan and losartan acid in human plasma by multiplexed LC-MS/MS.
Topics: Acids; Antihypertensive Agents; Chromatography, Liquid; Humans; Hydroflumethiazide; Imidazoles; Losartan; Molecular Structure; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tetrazoles | 2009 |
Hypertension study in anaesthetized rabbits: protocol proposal for AT1 antagonists screening.
Topics: Anesthesia; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Hypertension; Imidazoles; Losartan; Rabbits; Receptor, Angiotensin, Type 1; Reproducibility of Results; Tetrazoles; Time Factors | 2010 |
A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.
Topics: Alanine; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Chlorocebus aethiops; COS Cells; Humans; Imidazoles; Inositol Phosphates; Irbesartan; Losartan; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; Telmisartan; Tetrazoles; Threonine; Valine; Valsartan | 2010 |
Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin.
Topics: Animals; Antioxidants; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Flavonoids; Herb-Drug Interactions; Imidazoles; Losartan; Male; Plant Extracts; Rats; Rats, Sprague-Dawley; Tetrazoles | 2010 |
Inhibitory effects of uraemic toxins 3-indoxyl sulfate and p-cresol on losartan metabolism in vitro.
Topics: Angiotensin II Type 1 Receptor Blockers; Aryl Hydrocarbon Hydroxylases; Cresols; Cytochrome P-450 CYP2C9; Humans; Imidazoles; In Vitro Techniques; Indican; Kidney Failure, Chronic; Losartan; Microsomes, Liver; Renal Dialysis; Tetrazoles; Uremia | 2010 |
The physicochemical properties, in vitro metabolism and pharmacokinetics of a novel ester prodrug of EXP3174.
Topics: Animals; Chemistry, Physical; Dogs; Dose-Response Relationship, Drug; Esters; Humans; Hydrogen-Ion Concentration; Imidazoles; Intestinal Mucosa; Intestines; Liver; Losartan; Male; Molecular Structure; Prodrugs; Rats; Rats, Sprague-Dawley; Solubility; Stereoisomerism; Tetrazoles; Tissue Distribution | 2010 |
Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats.
Topics: Animals; Antihypertensive Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cell Line; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Imidazoles; Inhibitory Concentration 50; Losartan; Male; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Tetrazoles; Ticlopidine | 2011 |
Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Topics: Acyl Coenzyme A; Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Injections, Intravenous; Losartan; Lovastatin; Male; Rats; Rats, Sprague-Dawley; Rhodamine 123; Simvastatin; Tetrazoles; Time Factors | 2011 |
Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.
Topics: Adult; Alleles; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C9; Gene Frequency; Genotype; Humans; Imidazoles; Losartan; Male; Tetrazoles; Young Adult | 2011 |
Pre-treatment with curcumin enhances plasma concentrations of losartan and its metabolite EXP3174 in rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antioxidants; Area Under Curve; Chromatography, High Pressure Liquid; Curcumin; Female; Imidazoles; Losartan; Male; Rats; Rats, Wistar; Tandem Mass Spectrometry; Tetrazoles | 2012 |
High-sensitivity liquid chromatography-tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Drug Stability; Humans; Imidazoles; Linear Models; Liquid-Liquid Extraction; Losartan; Omeprazole; Pharmaceutical Preparations; Reproducibility of Results; Tandem Mass Spectrometry; Tetrazoles; Theophylline | 2012 |
Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes.
Topics: Adult; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C9; Female; Genotype; Humans; Hydroxylation; Imidazoles; Losartan; Male; Middle Aged; Phenotype; Tetrazoles | 2012 |
Pharmacokinetic interaction between losartan and Rhodiola rosea in rabbits.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Female; Herb-Drug Interactions; Imidazoles; Losartan; Plant Extracts; Rabbits; Rhodiola; Tetrazoles | 2013 |
Influence of compound danshen tablet on the pharmacokinetics of losartan and its metabolite EXP3174 by liquid chromatography coupled with mass spectrometry.
Topics: Animals; Chromatography, Liquid; Drug Stability; Drugs, Chinese Herbal; Herb-Drug Interactions; Imidazoles; Losartan; Male; Mass Spectrometry; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Salvia miltiorrhiza; Sensitivity and Specificity; Tetrazoles | 2013 |
Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.
Topics: Adult; Antibiotics, Antitubercular; Asian People; Caffeine; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Imidazoles; Losartan; Male; Midazolam; Omeprazole; Rifampin; Tetrazoles; Theophylline; Time Factors; Withholding Treatment | 2013 |
The influence of food on the pharmacokinetics of amlodipine and losartan after single-dose of its compound tablets in healthy chinese subjects.
Topics: Administration, Oral; Adult; Amlodipine; Area Under Curve; Asian People; Female; Food; Food-Drug Interactions; Humans; Imidazoles; Losartan; Male; Tablets; Tetrazoles; Young Adult | 2014 |
Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Chalcones; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dietary Supplements; Drug Interactions; Fluorescent Dyes; Half-Life; Imidazoles; Losartan; Male; Rats; Rats, Sprague-Dawley; Rhodamine 123; Tetrazoles | 2013 |
[Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves].
Topics: Adult; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cardiovascular Agents; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Drug Monitoring; Female; Genotype; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Humans; Imidazoles; Losartan; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Postoperative Period; Tetrazoles; Warfarin | 2013 |
Nanoparticle multivalency counterbalances the ligand affinity loss upon PEGylation.
Topics: Animals; Anti-Arrhythmia Agents; Cell Line, Tumor; Colloids; Drug Delivery Systems; Humans; Imidazoles; Ligands; Losartan; Nanoparticles; Polyethylene Glycols; Rats; Receptor, Angiotensin, Type 1; Tetrazoles | 2014 |
Lower CYP2C9 activity in Turkish patients with Behçet's disease compared to healthy subjects: a down-regulation due to inflammation?
Topics: Adult; Aged; Alleles; Behcet Syndrome; Chromatography, High Pressure Liquid; Colchicine; Cytochrome P-450 CYP2C9; Cytokines; Down-Regulation; Female; Genotype; Humans; Imidazoles; Inflammation; Losartan; Male; Middle Aged; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Tetrazoles; Turkey | 2015 |
Branched Polymer-Drug Conjugates for Multivalent Blockade of Angiotensin II Receptors.
Topics: Animals; Antihypertensive Agents; Cells, Cultured; Dendrimers; Drug Carriers; Drug Delivery Systems; Half-Life; Imidazoles; Ligands; Losartan; Mesoderm; Polyamines; Polyethylene Glycols; Polymers; Rats; Receptors, Angiotensin; Tetrazoles | 2015 |
Evaluation of [(11)C]methyl-losartan and [(11)C]methyl-EXP3174 for PET imaging of renal AT1receptor in rats.
Topics: Animals; Carbon Radioisotopes; Imidazoles; Kidney; Losartan; Male; Positron-Emission Tomography; Radiochemistry; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Tissue Distribution | 2015 |
Multivalent nanoparticles bind the retinal and choroidal vasculature.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Binding, Competitive; Calcium Signaling; Capillaries; Choroid; Drug Carriers; HeLa Cells; Humans; Injections, Intravenous; Losartan; Mice; Protein Binding; Quantum Dots; Receptor, Angiotensin, Type 1; Retinal Vessels; Surface Properties; Tissue Distribution | 2015 |
Negligible Pharmacokinetic Interaction of Red Ginseng and Losartan, an Antihypertensive Agent, in Sprague-Dawley Rats.
Topics: Administration, Intravenous; Administration, Oral; Animals; Antihypertensive Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Imidazoles; Losartan; Male; Panax; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tetrazoles | 2015 |
The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.
Topics: Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Genotype; Humans; Inhibitory Concentration 50; Losartan; Microsomes, Liver; Paclitaxel; Taxoids | 2016 |
Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9.
Topics: Abietanes; Animals; Antihypertensive Agents; Benzofurans; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Drugs, Chinese Herbal; Losartan; Male; Mass Spectrometry; Microsomes, Liver; Rats, Sprague-Dawley; RNA, Messenger | 2016 |
[EVALUATION OF THE PHARMACOKINETIC INTERACTION OF AFOBAZOLE WITH CYP2C9 ENZYME DRUG SUBSTRATE OF CYTOCHROME P450].
Topics: Animals; Animals, Outbred Strains; Anti-Anxiety Agents; Area Under Curve; Benzimidazoles; Biotransformation; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2C9 Inducers; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Imidazoles; Losartan; Male; Morpholines; Rats; Tetrazoles | 2015 |
Mechanical activation of angiotensin II type 1 receptors causes actin remodelling and myogenic responsiveness in skeletal muscle arterioles.
Topics: Abdominal Muscles; Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterioles; Benzimidazoles; Biphenyl Compounds; Captopril; Cells, Cultured; Diglycerides; Imidazoles; Indoles; Losartan; Male; Maleimides; Muscle Development; Muscle Fibers, Skeletal; Pressure; Protein Kinase C; Pyridines; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Vasoconstriction; Vasoconstrictor Agents | 2016 |
Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cell Line; Connective Tissue Growth Factor; Fibrosis; Humans; Losartan; Male; Myocardium; Myofibroblasts; Protein-Lysine 6-Oxidase; Rats; Rats, Wistar; Transforming Growth Factor beta; Ventricular Dysfunction, Left | 2017 |
The effect of tripterygium glucoside tablet on pharmacokinetics of losartan and its metabolite EXP3174 in rats.
Topics: Animals; Chromatography, Liquid; Glucosides; Herb-Drug Interactions; Losartan; Male; Mass Spectrometry; Microsomes, Liver; Plant Extracts; Rats; Rats, Sprague-Dawley; Tablets; Tripterygium | 2017 |
Conjugation to Ascorbic Acid Enhances Brain Availability of Losartan Carboxylic Acid and Protects Against Parkinsonism in Rats.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Ascorbic Acid; Behavior, Animal; Biological Availability; Brain; Disease Models, Animal; Drug Evaluation, Preclinical; Haloperidol; Humans; Losartan; Male; Parkinsonian Disorders; Rats; Rats, Wistar; Renin-Angiotensin System | 2018 |
Modelling gastric emptying: A pharmacokinetic model simultaneously describing distribution of losartan and its active metabolite EXP-3174.
Topics: Administration, Oral; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Cross-Over Studies; Female; Gastric Emptying; Humans; Losartan; Male; Models, Biological; Therapeutic Equivalency; Young Adult | 2020 |
Losartan metabolite EXP3174 reduces the weight of formed thrombus in 2K1C hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Coagulation; Blood Platelets; Blood Pressure; Hemostasis; Hypertension, Renovascular; Losartan; Male; Platelet Aggregation; Rats; Rats, Wistar; Thrombosis; Venous Thrombosis | 2019 |
Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Endothelium; Imidazoles; Losartan; Mice; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1 | 2022 |
Sartan blood pressure regulators in classical and biofilm wastewater treatment - Concentrations and metabolism.
Topics: Angiotensin II Type 1 Receptor Blockers; Biofilms; Blood Pressure; Humans; Irbesartan; Losartan; Sewage; Valsartan; Wastewater; Water Pollutants, Chemical; Water Purification | 2023 |
Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Humans; Hypertension; Losartan; Polymorphism, Genetic; Uric Acid | 2023 |
Simultaneous quantification of losartan potassium and its active metabolite, EXP3174, in rabbit plasma by validated HPLC-PDA.
Topics: Animals; Chromatography, High Pressure Liquid; Losartan; Quality Control; Rabbits; Reproducibility of Results; Valsartan | 2023 |
Metabolomic Profile and Its Correlation with the Plasmatic Levels of Losartan, EXP3174 and Blood Pressure Control in Hypertensive and Chronic Kidney Disease Patients.
Topics: Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Losartan; Renal Insufficiency, Chronic; Urea | 2023 |
Allisartan Isoproxil Promotes Uric Acid Excretion by Interacting with Intestinal Urate Transporters in Hyperuricemic Zebrafish (Danio rerio).
Topics: Animals; Hyperuricemia; Kidney; Losartan; Uric Acid; Zebrafish | 2023 |